Today's daily common blog features two of Unnati Pharmax's most impactful antiviral products for our four daily common markets — Tafero EM for HIV prevention and Resof L for Hepatitis C cure — both delivering WHO-quality clinical outcomes at dramatically more accessible pricing.
In the Philippines, Tafero EM's role in HIV PrEP has never been more critical — HIV incidence among Filipino MSM communities continues to rise, and affordable PrEP access in Metro Manila, Davao, and Cebu is a genuine public health emergency response tool. Meanwhile, Resof L provides Hepatitis C cure for Filipino patients who cannot access expensive branded DAA therapy. In South Africa, both HIV prevention (for HIV-negative people at risk) and HIV treatment (Spegra for positive individuals) are critical — but Resof L also serves South Africa's significant HCV burden, particularly among people who inject drugs in Cape Town and Johannesburg. In Australia and Singapore, both products serve international students, migrants, and tourists requiring supply outside domestic healthcare programmes.
Full WHO-GMP documentation, certificates of analysis, and DHL/FedEx international shipping with tracking. Visit medshopy.com or WhatsApp +91 82650 41513.
In the Philippines, Tafero EM's role in HIV PrEP has never been more critical — HIV incidence among Filipino MSM communities continues to rise, and affordable PrEP access in Metro Manila, Davao, and Cebu is a genuine public health emergency response tool. Meanwhile, Resof L provides Hepatitis C cure for Filipino patients who cannot access expensive branded DAA therapy. In South Africa, both HIV prevention (for HIV-negative people at risk) and HIV treatment (Spegra for positive individuals) are critical — but Resof L also serves South Africa's significant HCV burden, particularly among people who inject drugs in Cape Town and Johannesburg. In Australia and Singapore, both products serve international students, migrants, and tourists requiring supply outside domestic healthcare programmes.
Full WHO-GMP documentation, certificates of analysis, and DHL/FedEx international shipping with tracking. Visit medshopy.com or WhatsApp +91 82650 41513.
Can someone be co-infected with both HIV and Hepatitis C simultaneously, and how is this managed?Yes — HIV/HCV co-infection is relatively common, particularly among people who inject drugs, since both viruses spread efficiently through blood-to-blood contact including needle sharing. Globally, estimates suggest approximately 2-3 million people are co-infected with both HIV and HCV. Co-infection is clinically significant because HIV accelerates HCV-related liver disease progression — co-infected patients develop liver cirrhosis approximately twice as fast as HCV mono-infected individuals. Management involves treating both infections, ideally sequentially or sometimes simultaneously depending on clinical urgency. Modern DAA therapy for HCV (like Resof L) is equally effective in HIV/HCV co-infected patients as in HCV mono-infected patients — achieving 95%+ SVR12 cure rates. Important drug interaction checking between DAA therapy and antiretroviral regimens is necessary, as some combinations interact. For patients managing both HIV (Tafero EM/Spegra) and HCV (Resof L), coordinating treatment with an experienced physician familiar with both conditions is essential.
